Key Metrics of Decoy Therapeutics Inc.
Revenue—FY 2023
Operating income−$12.9M▲ 59.5% YoY
Net profit$12.5M▲ 139.7% YoY
Shareholders' equity$5.3M
Market cap$2.7MDCOY · $1.14
Competitors10identified
About Decoy Therapeutics Inc.
Sectors
Company details
- Founded
- 2015
- Listed
- Nasdaq: DCOY (since 2015)
Operational Areas of Decoy Therapeutics Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameDecoy Therapeutics Inc.
TickerDCOY
ExchangeNasdaq
CountryUnited States
SEC CIK0001615219
Listed since2015
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
DCOY · Nasdaq · SEC CIK 0001615219
Last price · 05 Nov 2026
$1.14
+2.70%
Market cap$2.7M
P/E—On FY 2023 diluted EPS
Volume16,677
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2015
DCOY share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Decoy Therapeutics Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Similar companies
E
Elanco Animal Health IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medtronic plc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Summit Therapeutics Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
ICON plc (ICLR)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Charles River Laboratories International Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ascendis Pharma A/S Ordinary SharePharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medpace Holdings Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
Insmed IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.